Aucta Company Profile
What is the competitive landscape for AUCTA
AUCTA has five approved drugs.
There are three US patents protecting AUCTA drugs.
Summary for Aucta
| US Patents: | 3 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Aucta
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aucta | ZELVYSIA | sapropterin dihydrochloride | FOR SOLUTION;ORAL | 218645-001 | Apr 29, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-002 | May 4, 2023 | RX | Yes | No | 11,337,943 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aucta | OXCARBAZEPINE | oxcarbazepine | SUSPENSION;ORAL | 215332-001 | Nov 30, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-003 | May 4, 2023 | RX | Yes | Yes | 12,042,474 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aucta | PYQUVI | deflazacort | SUSPENSION;ORAL | 219417-001 | Jun 30, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aucta | FOSFOMYCIN TROMETHAMINE | fosfomycin tromethamine | FOR SOLUTION;ORAL | 217772-001 | Apr 9, 2026 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aucta Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Finland | 3981390 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2020244615 | ⤷ Start Trial |
| Denmark | 3981390 | ⤷ Start Trial |
| Poland | 3981390 | ⤷ Start Trial |
| Finland | 3981390 | ⤷ Start Trial |
| Slovenia | 3981390 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Aucta Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0888289 | SPC/GB09/007 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829 |
| 0888289 | C300376 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE: EU/1/08/470/001-016 20080829 |
| 0888289 | 09C0006 | France | ⤷ Start Trial | PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/470/001 DU 20080829; REGISTRATION NO/DATE AT EEC: EU/1/08/470/001 DU 20080829 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
